Literature DB >> 30847275

Pulmonary sclerosing pneumocytoma, a rare tumor of the lung.

Burcu Yalcin1, Taha Tahir Bekci1, Sumeyye Kozacioglu2, Ozden Bolukbas3.   

Abstract

Pulmonary sclerosing pneumocytoma (PSP) is a rare benign pulmonary tumor. Usually diagnosed incidentally by chest X-ray or chest CT scan. We presented a case of PSP in a 50-year-old woman who was diagnosed with a nodular lesion in the right lung. Thoracotomy was used for the excision of the mass. Pathologic examination revealed no malignant cells. Immunohistochemical studies were performed. TTF-1 was (+), Napsin-A was found to be weakly (+). After surgical resection, the patient was followed up.

Entities:  

Year:  2019        PMID: 30847275      PMCID: PMC6389774          DOI: 10.1016/j.rmcr.2019.02.002

Source DB:  PubMed          Journal:  Respir Med Case Rep        ISSN: 2213-0071


Introduction

Pulmonary sclerosing pneumocyte (PSP), formerly known as pulmonary sclerosing hemangioma, is a rare pulmonary tumor initially described by Liebow et al., In 1956 as a tumor with marked sclerosis and vascularization [1]. PSP is usually seen in adults over 50 years old, with a female to male ratio of 5: 1 [2,3]. PSP has been shown to be the primitive epithelial origin, most likely from type II alveolar pneumocytes by Immunohistochemical markers [2]. The essential feature of the PSP is the presence of cuboidal surface cells and stromal round cells, both of which are thought to be neoplastic [4]. In the 2015 World Health Organization (WHO) classification, “miscellaneous tumors” have been switched to “adenomas” [5]. We are presenting this PSP case, it is rare, benign disease, might be confused with malignities and there are difficulties in its diagnosis and treatment.

Case report

A 50-year-old female patient applied to our clinic in March 2017 after a nodular lesion in her right lung was detected in another hospital. The patient had no complaints, no smoking or tuberculosis history. There was no significant trait in her clinical history. She was not using any medication. Vital findings were followed, as blood pressure arterial 120/70, pulse rate 90/min, respiratory rate 14/min and Oxygen saturation in room air 97%. Her respiratory system examination was normal. WBC 8200, hmg 14.1, Plt 400000, urea 24, creatinine was 0.6. Contrast-enhanced Thorax CT showed a well-defined, hypodense soft-tissue lesion in the size of 28 × 16 mm closely located to the right inferior pulmonary vein (Fig. 1). In PET-CT, a mass of soft tissue with a lobulated contour with no evidence of increased FDG uptake was detected in the superior segment of the right lower lobe of the lungs in the medial paramediastinal area in sizes of 31 × 22 mm. A transthoracic biopsy was planned under the guidance of tomography but the patient refused. Endobronchial pathology was not detected by fiber opticbronchoscopy. The patient was then referred to thoracic surgery who proceeded to a right lateral thoracotomy. Frozen sample was sent during right lateral thoracotomy. Immunohistochemistry analysis of the resected lesion showed positive (+) with TTF-1, bcl-2 and pansitokeratin, weakly (+) with Napsin-A and CD99 and negative with CD34 (Fig. 2, Fig. 3) consistent with sclerosing pneumocytoma. Sclerosing pneumocytoma was detected after incisional biopsy of the lower lobe of the right lung. Postoperative complications did not develop and the patient was followed-up.
Fig. 1

Contrast-enhanced Thorax CT showed hypodense soft-tissue lesion in the size of 28 × 16 mm closely located to the right inferior pulmonary vein.

Fig. 2

HE stain shows sclerosing papillary structures are covered by surface cells (50X).

Fig. 3

The surface cells are positive for pancytokeratin and TTF-1 immunohistochemically (100X).

Contrast-enhanced Thorax CT showed hypodense soft-tissue lesion in the size of 28 × 16 mm closely located to the right inferior pulmonary vein. HE stain shows sclerosing papillary structures are covered by surface cells (50X). The surface cells are positive for pancytokeratin and TTF-1 immunohistochemically (100X).

Discussion

PSP is a benign tumor with low prevalence. It is often seen in middle-aged Asian women. Patients are usually asymptomatic and it is detected coincidentally. A cough, chest pain and hemoptysis may also occur [6]. Although PSP is often solitary, well-defined, round or oval, homogeneous nodule or mass, there is no definitive diagnostic radiographic finding [7]. However, there are also cases of metastases to the lymph nodes, pleura, and bones [[8], [9], [10]]. Patients may present with a mass lesion of up to 7 cm through 73% of the lesions are below 3 cm [2,4]. Our case had also applied to our clinic with a mass lesion that was detected incidentally. “Air meniscus sign” is a sign for pneumoconiosis [11]. Marginal pseudocapsules (50%), overlying vessels (26.3%), air gap (2.6%) and halo sign (17.1%) are among thoracic CT findings [7]. Sometimes pleural-based, polypoid lesions may mimic a solitary fibrous tumor. Four typical structural patterns are defined in the PSP; papillary, sclerotic, solid and hemorrhagic. Often the tumor consists of superficial cuboidal and round interstitial cells with a combination of four patterns. If the papillary component of the sclerosing pneumocytoma in the biopsy material is predominant, the diagnosis may be difficult. In addition, both superficial cuboidal cells and round interstitial cells are positively immunoreactive for TTF1 and EMA [2,12]. TTF1 is used in the diagnosis of lung adenocarcinoma and may be misleading for PSP. Napsin A, a human aspartic proteinase, shows immnohistochemical reactivity in type II pneumocytes with a granular and cytoplasmic staining pattern [13]. It has been widely used in the panel of diagnosis of lung adenocarcinoma along with TTF-1 [14]. Recently it has been demonstrated that Napsin A preferentially stains cuboidal surface cells, not the stromal round cells in sclerosingpneumocytoma [15,16]. The round cells are generally uniformly negative for pan-cytokeratin and positive for cytokeratin-7 and CAM 5.2 in few cases [2]. P53 mutation was exhibited in primary SH. The mutation rate in polygonal cells was higher than that in surface cuboidal cells [17]. The treatment of PSPs is based on surgical resection. Rarely, these tumors can lead to hemoptysis or airway obstruction and respiratory failure [18]. In the study by Park et al. it was determined that wedge resection or enucleation is curative [19]. However, recently, different treatment approaches have been suggested. In a published case report, radiological follow-up decision was taken for a patient diagnosed with PSP by biopsy [20]. It is appropriate that each patient is assessed in a multidisciplinary fashion. Radiotherapy was also suggested as an alternative treatment for inoperable patients [21].

Conclusion

PSP is an asymptomatic, rare benign neoplasm. It is mostly incidental. Histologically, it contains two epithelial cell types, surface cells and round cells, which consist of four structural patterns. Preoperative diagnosis is difficult. Surgical excision alone is sufficient for treatment.

Conflicts of interest

The authors have no conflicts of interest relevant to this article to disclose.

Funding sources and financial disclosure

No funding was secured for this study, and the authors have no financial relationships relevant to this article to disclose.
  20 in total

1.  Sclerosing hemangioma (histiocytoma, xanthoma) of the lung.

Authors:  A A LIEBOW; D S HUBBELL
Journal:  Cancer       Date:  1956 Jan-Feb       Impact factor: 6.860

2.  [Sclerosing hemangioma presenting as a solitary lung nodule. Report of one case].

Authors:  Gonzalo Cardemil; Eduardo Fernández; Paola Riffo; Diego Reyes; Rodrigo Ledezma; Magdalena Mira; Claudia Morales; Jorge Salguero
Journal:  Rev Med Chil       Date:  2004-07       Impact factor: 0.553

3.  Napsin A expression in pulmonary sclerosing haemangioma.

Authors:  Giulio Rossi; Annamaria Cadioli; Maria Cecilia Mengoli; Silvia Piccioli; Alberto Cavazza
Journal:  Histopathology       Date:  2011-11-10       Impact factor: 5.087

4.  p53 protein expression and genetic mutation in two primary cell types in pulmonary sclerosing haemangioma.

Authors:  Y Wang; S-D Dai; F-J Qi; H-T Xu; E-H Wang
Journal:  J Clin Pathol       Date:  2007-08-17       Impact factor: 3.411

5.  Expression of thyroid transcription factor-1 and other markers in sclerosing hemangioma of the lung.

Authors:  P B Illei; J Rosai; D S Klimstra
Journal:  Arch Pathol Lab Med       Date:  2001-10       Impact factor: 5.534

6.  A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium.

Authors:  M Devouassoux-Shisheboran; T Hayashi; R I Linnoila; M N Koss; W D Travis
Journal:  Am J Surg Pathol       Date:  2000-07       Impact factor: 6.394

7.  Clinicopathological analysis of pulmonary sclerosing hemangioma.

Authors:  Akira Iyoda; Kenzo Hiroshima; Mitsutoshi Shiba; Yukiko Haga; Yasumitsu Moriya; Yasuo Sekine; Kiyoshi Shibuya; Toshihiko Iizasa; Takehiko Fujisawa
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

8.  Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis.

Authors:  A C Chan; J K Chan
Journal:  Am J Surg Pathol       Date:  2000-11       Impact factor: 6.394

9.  Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection.

Authors:  Joon Seok Park; Kwhanmien Kim; Sumin Shin; Hunbo Shim; Hong Kwan Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-02-12

10.  Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A.

Authors:  T Hirano; G Auer; M Maeda; Y Hagiwara; S Okada; T Ohira; K Okuzawa; K Fujioka; B Franzén; N Hibi; T Seito; Y Ebihara; H Kato
Journal:  Jpn J Cancer Res       Date:  2000-10
View more
  2 in total

1.  A case of pulmonary sclerosing pneumocytoma diagnosed preoperatively using transbronchial cryobiopsy.

Authors:  Yutaka Muto; Naoyuki Kuse; Minoru Inomata; Nobuyasu Awano; Mari Tone; Jonsu Minami; Kohei Takada; Kazushi Fujimoto; Ami Wada; Keita Nakao; Yoshiaki Furuhata; Chisa Hori; Yuan Bae; Toshio Kumasaka; Takehiro Izumo
Journal:  Respir Med Case Rep       Date:  2021-08-11

Review 2.  Pulmonary Sclerosing Pneumocytoma: A Pre and Intraoperative Diagnostic Challenge. Report of Two Cases and Review of the Literature.

Authors:  Senia Maria Rosaria Trabucco; Debora Brascia; Gerardo Cazzato; Giulia De Iaco; Anna Colagrande; Francesca Signore; Giuseppe Ingravallo; Leonardo Resta; Giuseppe Marulli
Journal:  Medicina (Kaunas)       Date:  2021-05-23       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.